Company Overview and News

2
JP Morgan’s top-performing fund manager counts on China’s youngster to defend her title

2018-06-14 scmp
The firm’s China Fund has delivered a 38pc return over the past year, thanks to gains from China’s online entertainment and private school stocks
3968 CHN

15
Xiaomi to be the first target of China’s unicorn funds, giving mainland investors a taste of marquee IPOs

2018-06-07 scmp
Six of the first funds will have a combined war chest of 300 billion yuan, more than the sum total of every A-share IPO last year, enough for them to act as cornerstone investors in the biggest blockbuster stock offers
CICHY 0941 3968 CHLKF CHL CICHF CCB 0939

1
China funds to boost support for domestic listings of tech giants: Report

2018-06-06 channelnewsasia
Six Chinese mutual funds will be launched as early as next Monday, potentially channeling hundreds of billions of yuan from investors into domestic floatations of overseas-listed Chinese tech giants, the Shanghai Securities News reported on Wednesday.
CICHY 3968 CICHF CCB 0939

1
China funds to boost support for domestic listings of tech giants - paper

2018-06-06 channelnewsasia
Six Chinese mutual funds will be launched as early as next Monday, potentially channeling hundreds of billions of yuan from investors into domestic floatations of overseas-listed Chinese tech giants, the Shanghai Securities News reported on Wednesday.
CICHY 3968 CICHF CCB 0939

79
China funds to boost support for domestic listings of tech giants - paper

2018-06-06 reuters
SHANGHAI (Reuters) - Six Chinese mutual funds will be launched as early as next Monday, potentially channeling hundreds of billions of yuan from investors into domestic floatations of overseas-listed Chinese tech giants, the Shanghai Securities News reported on Wednesday.
CICHY 3968 BABA CICHF CCB 0939

0
Chinese banks in push to spin-off asset management units

2018-06-03 scmp
Banks in China are vying to set up independent asset management subsidiaries to cope with tighter regulations on wealth management that aim to break implicit guarantees of banking products worth 30 trillion yuan (US$4.7 trillion).
3968

2
Anbang’s Long, Slow Road to Redemption - Bloomberg

2018-05-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CGMBF 3968 2628 UBS UBS.PRDCL LFC CMAKY ULSGF

12
Chinese banks up the ante to lure millionaire clients from overseas private investment houses

2018-05-22 scmp
More than 60pc of mainlanders with personable investible assets worth in excess of US$1 million now hold those offshore, and 10 per cent of that by value are handled by foreign banks
3968 MS.PRI MS.PRK 55BC MS.PRE MS.PRF MS.PRG MS CBQS MS.PRA

0
Chinese banks, pitching safety and returns (maybe), lure customers into deposits

2018-05-10 reuters
SHANGHAI (Reuters) - At a Hua Xia Bank branch in Shanghai’s financial district, Wang Shujuan, a 72-year-old retired doctor, is looking at moving her money out of a high-yielding wealth management product into a bank deposit bearing an indefinite rate of return.
3968

0
Chinese firms slow to reduce share-backed loans despite regulator crackdown

2018-05-09 reuters
SHANGHAI/HONG KONG (Reuters) - Chinese companies are only gradually reducing the amount of shares pledged for loans despite curbs by regulators as part of efforts to reduce the risk the deals pose to market stability.
3968

0
Hong Kong stocks rise as financials climb

2018-04-30 thehindubusinessline
Hong Kong’s main Hang Seng index rose to a more than one-week high by lunch break on Monday, as strength in overseas markets provided support, with banks and financial stocks leading the charge, while China's H-shares index climbed to an over two-week high.
3968 0914 1088

34
How to Run Hedge Funds in a Communist Country - Bloomberg

2018-04-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
3968 BLK UBS 55BC UBS.PRDCL CBQS ULSGF

4
Cheniere upsizes financing for Corpus Christi LNG to $6.4 billion

2018-04-23 worldoil
HOUSTON -- Cheniere Energy, Inc., has announced that its wholly owned subsidiary Cheniere Corpus Christi Holdings, LLC, has engaged financial institutions to act as Joint Lead Arrangers to assist in the structuring and arranging of up to $6.4 billion of credit facilities. Corpus Christi Holdings will amend and upsize its existing approximately $4.6 billion of credit facilities to increase the available commitments.
3968 CQP LNG 55BC BVA CBQS

222
Venture Capital Deals Of The Week: Alibaba Invests $717M In Rural China

2018-04-21 seekingalpha
Rural China e-commerce: Alibaba (NYSE:BABA) invested $717M in Huitongda Network Co., an e-commerce platform that could expand the tech giant’s sales reach to rural areas. Other investors include Shunwei Capital, China Merchants Bank, and Jiangsu Govtor Capital. The funding brought
JD 3968 BABA DVMT MSFT CVLT NTNX

0
Bank of Singapore to double wealth management staff in Hong Kong to cater to China’s rich

2018-04-17 scmp
Bank also plans to set up family offices in major Chinese cities this year to help the wealthy with inheritance planning
3968

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

10h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...